This article from 25/4/23 talks to Neurofilament Light Chain as a surrogate endpoint in Neurology trials being accepted by FDA.
It is a press release from Quanterin Corp, the owners of SIMOA assay.
I'm not sure if it has been posted before, I know there has been discussion on Tofersen, but this article really highlights the critical nature of this biomarker.
The first 2 results were just the warm up act ... the main show is just about to begin.
https://www.businesswire.com/news/home/20230425005796/en/FDA-Accelerated-Approval-of-Tofersen-Highlights-Importance-of-Blood-Neurofilament-Light-Chain-as-Surrogate-Endpoint-in-Neurology-Therapeutic-Trials
Ann: MND Biomarkers and Pharmacodynamics Results, page-333
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.010(5.41%) |
Mkt cap ! $93.42M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 19.0¢ | $28.67K | 148.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 241621 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 25618 | 3 |
View Market Depth
| Last trade - 12.58pm 19/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |